Plain-English translation of NCT07377487 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing TheraSphere, a treatment that uses tiny radioactive beads delivered directly to liver tumors to shrink them and slow cancer growth. The trial is for Japanese patients with primary or secondary liver cancer who either didn't respond to standard treatments or aren't able to have them. Researchers want to understand how safe and effective this treatment is for these patients.
Many people with advanced liver cancer cannot benefit from surgery or standard chemotherapy because their cancer is too advanced or their liver function is too weak. This trial exists to see whether this targeted radiation treatment can help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would come to the hospital for the TheraSphere procedure, which involves a catheter (thin tube) placed into blood vessels leading to your liver tumor—this is similar to an angiography procedure. After treatment, you will have follow-up imaging and blood tests to see how your cancer responds and to monitor for any side effects. The study will track your health and tumor status over time to evaluate whether this treatment is helping you.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
Japan
Sponsor
Boston Scientific Corporation
Enrollment target
~51 participants
Started
January 2026
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Satoru Motohashi
Hyogo Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.